ArticleEmerging microbes & infections2019
A neonatal murine model of coxsackievirus A4 infection for evaluation of vaccines and antiviral drugs.
Article in Emerging microbes & infections, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 18 citations in OpenAlex.
- Neurotropism and interferon-dominated immune responses in a mouse-adapted coxsackievirus A16 infection model.Journal of virology · 2026Article
- Genetic Analysis of Coxsackievirus A4 Among Healthy Children - Xizang Autonomous Region, China, 1996-2024.China CDC weekly · 2026Article
- Establishment of severe in vitro and in vivo infection models for coxsackievirus B4 and their application in identifying viral virulence determinants.Virologica Sinica · 2026Article
- Pathological characteristics of coxsackievirus A14 in neonatal mice model.Virology journal · 2026Article
- A lethal juvenile mouse model for the evaluation of antiviral reagents against coxsackievirus A4.iScience · 2025Article
- Establishment and application of a wild neonatal mouse model infected with an Echovirus 30 isolate.Virology journal · 2025Article
- Humoral and cellular immunogenicity and efficacy of a coxsackievirus A10 vaccine in mice.Emerging microbes & infections · 2023Article
- Article
- The development and characterization of a stable Coxsackievirus A16 infectious clone with Nanoluc reporter gene.Frontiers in microbiology · 2022Article
- Pathological Features of Echovirus-11-Associated Brain Damage in Mice Based on RNA-Seq Analysis.Viruses · 2021Article
- Efficacy of a coxsackievirus A6 vaccine candidate in an actively immunized mouse model.Emerging microbes & infections · 2021Article
- Efficacy of Coxsackievirus A5 Vaccine Candidates in an Actively Immunized Mouse Model.Journal of virology · 2021Article
- A 10-Day-Old Murine Model of Coxsackievirus A6 Infection for the Evaluation of Vaccines and Antiviral Drugs.Frontiers in immunology · 2021Article
- Th1/Th2 Cells and Associated Cytokines in Acute Hepatitis E and Related Acute Liver Failure.Journal of immunology research · 2020Article
- A review of enterovirus-associated hand-foot and mouth disease: preventive strategies and the need for a global enterovirus surveillance network.Pathogens and global healthReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coxsackievirus A4 (CVA4) infection can cause hand, foot and mouth disease (HFMD), an epidemic illness affecting neonatal and paediatric cohorts, which can develop to severe neurological disease with high mortality. In this study, we established the first ICR mouse model of CVA4 infection for the evaluation of inactivated vaccines and antiviral drug screening. The CVA4 YT226R strain was selected to infect the neonatal mice and three infectious factors were optimized to establish the infection model. The 3-day-old neonatal mice exhibited clinical symptoms such as hind limb paralysis and death. The severe inflammatory reactions were closely related to the abnormal expression of the acute phase response proinflammatory cytokine IL-6 and an imbalance in the IFN-γ/IL-4 ratio. Importantly, the inactivated CVA4 whole-virus vaccine induced humoral immune responses in adult females and the maternal antibodies afforded mice complete protection against lethal dose challenges of homologous or heterologous CVA4 strains. Both IFN-α2a and antiserum inhibited the replication of CVA4 and increased the survival rates of neonatal mice during the early stages of infection. This neonatal murine model of CVA4 infection will be useful for the development of prophylactic and therapeutic vaccines and for screening of antiviral drugs targeting CVA4 to decrease morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.